Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-AFP in Rectovaginal Fistulizing Crohn's Disease
NCT03220243Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Oct 2017
- Primary completion
- Sep 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Autologous mesenchymal stromal cell coated fistula plug in rectovaginal fistula (RVF), sponsored by Mayo Clinic. Primary endpoint: Adverse Events at 24 months. Started Oct 2017; status: completed.
02
Drugs
Autologous mesenchymal stromal cell coated fistula plug
03
Conditions
rectovaginal fistula (RVF)
Beyond the preview
Go deeper on NCT03220243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220243.